Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K
J Clin Endocrinol Metab. 1987 Aug;65(2):324-30. doi: 10.1210/jcem-65-2-324.
Thyroid-stimulating antibody (TSAb) and TSH binding inhibitor immunoglobulin (TBII) were measured serially in 10 patients with Graves' disease at the time of postpartum onset (n = 2) or relapse (n = 8) of Graves' thyrotoxicosis and in 5 patients with Graves' disease who were in remission and had no postpartum relapse of Graves' thyrotoxicosis. TSAb was measured by a sensitive cAMP accumulation assay using FRTL-5 cells, and TBII was determined by radioreceptor assay. In no patient with either recurrent or new onset postpartum hyperthyroidism did the serum free T3 index (FT3I) rise before the free T4 index (FT4I). Of the 10 patients who had postpartum thyrotoxicosis, concomitant increases in serum FT4I and FT3I, and TSAb and TBII were observed in only 1 patient. Increases in TSAb and TBII after those in FT4I and FT3I occurred in 6 patients. In 1 patient, an increase in TBII was associated with the occurrence of thyrotoxicosis, but TSAb increased 1 month later. In the other 2 patients, a TSAb increase was followed by the development of thyrotoxicosis, but TBII increased later. In 3 of these 10 patients, the increased serum FT4I and FT3I values decreased spontaneously, whereas the TSAb and TBII levels increased continuously. No positive test or increase in TSAb or TBII was found in the 5 patients with Graves' disease who did not have a postpartum relapse of thyrotoxicosis. These data indicate that postpartum initiation of Graves' thyrotoxicosis is not always associated with an increase in circulating anti-TSH receptor antibodies and that such parameters are poor indicators of thyroid function. Intrathyroidal humoral or cell-mediated immunological mechanisms may also be involved in mediating thyrotoxicosis in Graves' disease.
对10例产后发生(n = 2)或复发(n = 8)格雷夫斯甲状腺毒症的格雷夫斯病患者以及5例处于缓解期且未发生产后格雷夫斯甲状腺毒症复发的格雷夫斯病患者,连续测定促甲状腺素抗体(TSAb)和促甲状腺素结合抑制性免疫球蛋白(TBII)。TSAb采用使用FRTL-5细胞的敏感环磷酸腺苷(cAMP)积累试验进行测定,TBII通过放射受体测定法确定。在产后复发性或新发甲亢患者中,血清游离T3指数(FT3I)均未先于游离T4指数(FT4I)升高。在10例产后甲状腺毒症患者中,仅1例患者血清FT4I和FT3I、TSAb和TBII同时升高。6例患者的TSAb和TBII在FT4I和FT3I升高之后升高。1例患者TBII升高与甲状腺毒症发生相关,但TSAb在1个月后升高。另外2例患者,TSAb升高后发生甲状腺毒症,但TBII随后升高。在这10例患者中的3例,血清FT4I和FT3I升高值自发下降,而TSAb和TBII水平持续升高。在5例未发生产后甲状腺毒症复发的格雷夫斯病患者中,未发现TSAb或TBII检测呈阳性或升高。这些数据表明,产后发生格雷夫斯甲状腺毒症并不总是与循环抗促甲状腺素受体抗体增加相关,且这些参数并非甲状腺功能的良好指标。甲状腺内体液或细胞介导的免疫机制也可能参与介导格雷夫斯病中的甲状腺毒症。